How do you see the benefit/safety risk equation shaping up for PCSK9 inhibitors based on the FOURIER and, most recently, the ODYSSEY Outcomes Trial?

How do you see the benefit/safety risk equation shaping up for PCSK9 inhibitors based on the FOURIER and, most recently, the ODYSSEY Outcomes Trial?

CLICK HERE FOR CME CREDIT

How do you see the benefit/safety risk equation shaping up for PCSK9 inhibitors based on the FOURIER and, most recently, the ODYSSEY Outcomes Trial? 

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Matthew Roe, MD

Matthew Roe, MD

Professor of Medicine Duke Clinical Research Institute Duke University School of Medicine Durham, NC